Market Overview

Benzinga's Top Initiations

Related SNTS
UPDATE: Stifel Downgrades Santarus Following SLXP Acquisition
Benzinga's Top Downgrades
Related SLXP
How Adam Feuerstein Follows The Biotech Sector
Deutsche Bank Slashes Price Target On Salix Pharmaceuticals
Making Money With Charles Payne: 10/17/14 (Fox Business)

Janney Capital initiated coverage on shares of Salix Pharmaceuticals (NASDAQ: SLXP) with a “buy” rating. The target price for Salix is set to $55. Salix's shares closed at $47.21 yesterday.

Analysts at Leerink initiated coverage on shares of Santarus (NASDAQ: SNTS) with a “outperform” rating. Santarus' shares closed at $12.93 yesterday.

JP Morgan initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ: INFI) with an “overweight” rating. The target price for Infinity Pharmaceuticals is set to $42. Infinity Pharmaceuticals' stock closed at $33.37 yesterday.

Analysts at Janney Capital initiated coverage on shares of Forest Laboratories (NYSE: FRX) with a “buy” rating. The target price for Forest Labs is set to $45. Forest Labs' shares closed at $36.28 yesterday.

Latest Ratings for SNTS

DateFirmActionFromTo
Dec 2013Stifel NicolausDowngradesBuyHold
Nov 2013Roth CapitalDowngradesBuyNeutral
Nov 2013Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for SNTS
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (INFI + FRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters